Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription 08.09.2025 1 AJR Am J Roentgenol 4 BJU Int 2 BMC Urol 1 Br J Cancer 3 Cancer 3 Cancer Res 4 Eur J Radiol 3 Int J Urol 1 J Magn Reson Imaging 1 J Urol 1 Lancet Oncol 1 Nat Rev Urol 2 Oncogene 1 Pol J Radiol 2 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. MARGOLIS DJA, Chatterjee A, deSouza NM, Fedorov A, et al
   Quantitative Prostate MRI, From the AJR Special Series on Quantitative Imaging.
   AJR Am J Roentgenol. 2024 Oct 2. doi: 10.2214/AJR.24.31715.
   PubMed         Abstract available
   
   

   
   BJU Int

2. DAUNGSUPAWONG H, Wiwanitkit V
   Comment on 'Socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency'.
   BJU Int. 2025 Sep 4. doi: 10.1111/bju.16922.
   PubMed        
   
   
3. VLAMING M, Koole W, van Moorselaar RJA, Bleiker EMA, et al
   Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer.
   BJU Int. 2025 Sep 2. doi: 10.1111/bju.16916.
   PubMed         Abstract available
   
   
4. BERTINI A, Cirulli GO, Stephens A, Finocchiaro A, et al
   Reply to 'Comment on Bertini et al.: area deprivation and PSA screening disparities' and 'Comment on socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency'.
   BJU Int. 2025 Sep 4. doi: 10.1111/bju.16924.
   PubMed        
   
   
5. ROBERTS IA, Cumberbatch MG, Catto JWF
   Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.
   BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
   PubMed         Abstract available
   
   

   
   BMC Urol

6. LUDECKE J, Mohr MN, Schneider TR, Voss JW, et al
   Combined robot-assisted surgery of upper and lower genitourinary tract with excellent early functional and oncological outcome - a case report of a concomitant nerve-sparing radical prostatectomy, diverticulectomy and ureterectomy.
   BMC Urol. 2025;25:225.
   PubMed         Abstract available
   
   
7. AGUILA-GIMENO O, Jareno-Vicens A, Recasens CT
   Pelvic floor rehabilitation before radical prostatectomy: a systematic review.
   BMC Urol. 2025;25:224.
   PubMed         Abstract available
   
   

   
   Br J Cancer

8. HUANG H, Benzonana LL, Zhao H, Watts HR, et al
   Correction to: Prostate cancer cell malignancy via modulation of HIF-1alpha pathway with isoflurane and propofol alone and in combination.
   Br J Cancer. 2025 Sep 5. doi: 10.1038/s41416-025-03175.
   PubMed        
   
   

   
   Cancer

9. NGUYEN DD, Satkunasivam R, Aminoltejari K, Hird A, et al
   Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study.
   Cancer. 2025;131:e70070.
   PubMed         Abstract available
   
   
10. NIERENGARTEN MB
    Outcomes show a reduction in treatment failure associated with dose-escalated, hypofractionated radiation therapy for localized prostate cancer.
    Cancer. 2025;131:e70013.
    PubMed        
    
    
11. NIERENGARTEN MB
    A persistent PSA level following radical prostatectomy for prostate cancer is associated with a worse prognosis.
    Cancer. 2025;131:e70012.
    PubMed        
    
    

    
    Cancer Res

12. JIANG J, Liu S, Xu C, He L, et al
    LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer.
    Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-0587.
    PubMed         Abstract available
    
    
13. MURPHY KC, DeMarco KD, Zhou L, Peura J, et al
    MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T Cell and Immunotherapy Responses in Prostate Cancer.
    Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-2532.
    PubMed         Abstract available
    
    
14. LIU S, Hsu EC, Aslan M, Garcia-Marques F, et al
    Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis.
    Cancer Res. 2025 Sep 5. doi: 10.1158/0008-5472.CAN-24-4855.
    PubMed         Abstract available
    
    

    
    Eur J Radiol

15. AGHAKHANYAN G, Barucci A, Pascali MA, Assante M, et al
    NAVIGATOR: A regional multimodal imaging biobank initiative powered by AI tools for precision medicine in oncology.
    Eur J Radiol. 2025;191:112327.
    PubMed         Abstract available
    
    
16. CURIA B, Bortolotto C, Brizzi L, Santagostini S, et al
    Impact on MRI technologist of a PI-QUAL v2 educational program on prostate MRI image quality assessment.
    Eur J Radiol. 2025;191:112280.
    PubMed         Abstract available
    
    
17. NATALI T, Kurucz LM, Fusaglia M, Mertens LS, et al
    Automatic prostate volume estimation in transabdominal ultrasound images.
    Eur J Radiol. 2025;191:112274.
    PubMed         Abstract available
    
    
18. BRENDER JR, Ota M, Nguyen N, Ford JW, et al
    Predicting ADC map quality from T2-weighted MRI: A deep learning approach for early quality assessment to assist point-of-care.
    Eur J Radiol. 2025;191:112317.
    PubMed         Abstract available
    
    

    
    Int J Urol

19. KAWASE M
    Editorial Comment Regarding "Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection".
    Int J Urol. 2025 Sep 1. doi: 10.1111/iju.70218.
    PubMed        
    
    
20. MATSUYAMA N, Suzuki K, Tobe T, Ueki H, et al
    Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Sep 2. doi: 10.1111/iju.70217.
    PubMed         Abstract available
    
    
21. SUZUKI K, Hirata J, Ueki H, Wakita N, et al
    Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis.
    Int J Urol. 2025 Sep 3. doi: 10.1111/iju.70219.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

22. LIU BC, Ding XH, Xu HH, Bai X, et al
    Preoperative Assessment of Extraprostatic Extension in Prostate Cancer Using an Interpretable Tabular Prior-Data Fitted Network-Based Radiomics Model From MRI.
    J Magn Reson Imaging. 2025 Sep 5. doi: 10.1002/jmri.70111.
    PubMed         Abstract available
    
    

    
    J Urol

23. CHEN DC, Alhamdani Z, Papa N, Shen E, et al
    The Blind Spot of PSMA-PET Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.
    J Urol. 2025 Sep 5:101097JU0000000000004734. doi: 10.1097/JU.0000000000004734.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

24. NIAZI T, Saad F, Tisseverasinghe S, Koul R, et al
    Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2025;26:1158-1167.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

25. FEIJO M, Carvalho TMA, Fonseca LRS, Vaz CV, et al
    Endocrine-disrupting chemicals as prostate carcinogens.
    Nat Rev Urol. 2025;22:609-631.
    PubMed         Abstract available
    
    

    
    Oncogene

26. CIVENNI G, Sandrini G, Merulla J, Musumeci C, et al
    Integrated control of cancer stemness by sigma(1) receptor in advanced prostate cancer.
    Oncogene. 2025 Sep 2. doi: 10.1038/s41388-025-03541.
    PubMed         Abstract available
    
    
27. RAZA M, Rajan AR, Kennedy BB, Reznicek TE, et al
    ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis.
    Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03559.
    PubMed         Abstract available
    
    

    
    Pol J Radiol

28. SARA HI, Aydin H, Hizli F
    The use of ADC histogram analysis in the diagnosis and determination of aggressiveness of peripheral zone prostate cancer.
    Pol J Radiol. 2025;90:e374-e383.
    PubMed         Abstract available
    
    

    
    Prostate

29. YUKIHIRO K, Sekino Y, Kobayashi G, Hatayama T, et al
    Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment.
    Prostate. 2025 Sep 1. doi: 10.1002/pros.70042.
    PubMed         Abstract available
    
    
30. MARTINEZ OSORIO CA, Sopena Sutil R, Vilaseca Cabo A, Linares Espinos E, et al
    Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide.
    Prostate. 2025 Sep 4. doi: 10.1002/pros.70040.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.